Health Monitoring in Mayotte. Update as of January 18, 2024.

Key points

Conjunctivitis

  • Increase in procedures for conjunctivitis-like conditions and in the dispensing of ophthalmic medications within the sentinel physician and pharmacist networks.

  • Initial laboratory findings indicate a viral infection for which antibiotics are not indicated in the absence of a bacterial superinfection.

Water shortage

  • In S02-2024, non-toxin-producing E. coli (DAEC) and enteropathogenic E. coli (EPEC) remained predominant in molecular biology analyses. The rates of samples testing positive for toxin-producing E. coli (ETEC) and enteroinvasive E. coli (Shigella) increased sharply between S1 and S2.

  • Sales of anti-diarrheal medications and oral rehydration solutions (ORS) in pharmacies in S02-2024 are once again above the highest level reported over the past 5 years.

  • Severe cases of GEA admitted to the intensive care unit at the Mayotte Hospital Center (CHM): 24 cases between S36-2023 and S02-2024; no new cases reported in S02.

  • Since January 15, 2024, water restrictions have been eased, and water is distributed every other day for 22 hours.

Bronchiolitis

  • The number of samples and the RSV positivity rate have been increasing for several weeks. Mayotte has been in a bronchiolitis epidemic since Week 51 of 2023.

Influenza

  • The positivity rate for Influenza A(H3N2) remains low, despite a slight increase in Week 02. As a reminder, the transition to the epidemic phase occurred in Week 44 of 2023.

In relation to

Our latest news

news

Launch of the “Heating, Health, Buildings, and Urban Planning” Network:...

news

2026 “Sexual Behavior” Survey (ERAS) for men who have sex with men

news

Hervé Maisonneuve has been appointed scientific integrity officer for a...